What Renflexis Pricing Says About Medicare's Biosimilars Policy
Executive Summary
Launch of a second infliximab biosimilar by Merck triggers Medicare's controversial biosimilars reimbursement policy for the first time.
You may also be interested in...
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.